Indications for excluding the seminal vesicles when treating clinically localized prostatic adenocarcinoma with radiotherapy alone

International Journal of Radiation Oncology Biology Physics

Volumn 37, Issue 4, 1997, Pages 871-876

  Katcher, Jerald ^a   Kupelian, Patrick A ^a   Zippe, Craig ^a   Klein, Eric A ^a   Sohn, Jason W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Conformal radiotherapy; Gleason score; Prostate specific antigen; Prostatic neoplasms; Seminal vesicles

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER RISK; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RECTUM; SCORING SYSTEM; SEMINAL VESICLE; TREATMENT INDICATION;

EID: 0030932878     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(96)00617-7     Document Type: Article

References (31)

1. Allain, Y. M.; Dixon, B.; Cellier, P.; Gamelin, E.; Geslin, J.; Larra, F.; Malkani, K.; Souaille, C.; Tuchais, C. Computed tomography in radiotherapy of prostate cancer. Bull. Cancer 74:407-413; 1987.
2. Corn, B. W.; Hanks, G. E.; Schultheiss, T. E.; Hunt, M. A.; Lee, W. R.; Coia, L. R. Conformal treatment of prostate cancer with improved targeting: Superior prostate-specific antigen response compared to standard treatment. Int. J. Radiat. Oncol. Biol. Phys. 32:325-330; 1995.
3. Diaz, A.; Roach, M.; Marquez, C.; Coleman, L.; Pickett, B.; Wolfe, J. S.; Carroll, P.; Narayan, P. Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 30:323-329; 1994.
4. Gleason, D. F. Veterans administration cooperative urological research group. Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum, M. ed. Urologic Pathology: The Prostate. Philadelphia: Lea & Febiger; 1977:171-198.
5. Hanks, G. E. External-beam radiation therapy for clinically localized prostate cancer: Patterns of care studies in the United States. Natl. Cancer Inst. Monogr. 7:75-84; 1988.
6. Hanks, G. E.; Lee, W. R.; Hanlon. A. L.; Kaplan, E.; Epstein, B.; Schultheiss, T. Conformal technique dose escalation in prostate cancer: Improved cancer control with higher doses in patients with pretreatment PSA ≤ 10 ng/mL. (Abstr.) Int. J. Radiat. Oncol. Biol. Phys. 32 (Suppl. 1):141-142; 1995.
7. Hanks, G. E.; Martz, K. L.; Diamond, J. J. The effect of dose on local control of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 15:1299-1305; 1988.
8. International Union Against Cancer. Urological tumours: prostate. In: Hermanek, P., Sobin, L., eds. TNM Classification of Malignant Tumours. New York: Springer-Verlag; 1987:141-144.
9. Lawton, C. A.; Won, M.; Pilepich, M. V.; Asbell, S. O.; Shipley, W. U.; Hanks, G. E.; Cox, J. D.; Perez, C. A.; Sause, W. T.; Doggett, S. R.; Rubin, P. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706. Int. J. Radiat. Oncol. Biol. Phys. 21:935-939; 1991.
10. Leibel, S. A.; Hanks, G. E.; Kramer, S. Patterns of care outcome studies: Results of the national practice in adenocar-cinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 10:401-409; 1984.
11. Leibel, S. A.; Zelefsky, M. J.; Kutcher, G. J.; Burman, C. M.; Kelson, S.; Fuks, Z. Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: Interim report of a phase 1 dose-escalation study. J. Urol. 152:1792-1798; 1994.
12. Leibel, S. A.; Zelefsky, M. J.; Kutcher, G. J.; Burman, C. M.; Mohan, R.; Mageras, G. S.; Ling, C. C.; Fuks, Z. The biological basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate. Semin. Oncol. 21:580-597; 1994.
13. Mameghan, H.; Fisher, R.; Mameghan, J.; Watt, W. H.; Tynan, A. Bowel complications after radiotherapy for carcinoma of the prostate: The volume effect. Int. J. Radiat. Oncol. Biol. Phys. 18:315-320; 1990.
14. Marks, L. B.; Anscher, M. S. Radiotherapy for prostate cancer: Should the seminal vesicles be considered target? Int. J. Radiat. Oncol. Biol. Phys. 24:435-440; 1992.
15. Oesterling, J. E.; Chan, D. W.; Epstein, J. I.; Kimball, A. W.; Bruzek, D. J.; Rock, R. C.; Brendler, C. B.; Walsh, P. C. Prostatic specific antigen in the preoperative and post-operative evaluation of localized prostatic cancer treated with radical prostatectomy. J. Urol. 139:766-772; 1988.
16. Partin, A. W.; Carter, H. B.; Chan, D. W.; Epstein, J. I.; Oesterling, J. E.; Rock, R. C.; Weber, J. P.; Walsh, P. C. Prostatic specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J. Urol. 143:747-752; 1990.
17. Partin, A. W.; Yoo, J.; Carter, H. B.; Pearson, J. D.; Chan, D. W.; Epstein, J. I.; Walsh, P. C. The use of prostate specific antigen, clinical stage and Gleason score to predict pathologic stage in men with localized prostate cancer. J. Urol. 150:110-114; 1993.
18. Perez, C. A.; Walz, B. J.; Zivnuska, F. R.; Pilepich, M.; Kurchity, P.; Bauer, W. Irradiation of carcinoma of the prostate localized to the pelvis: Analysis of tumor response and prognosis. Int. J. Radiat. Oncol. Biol. Phys. 6:555-563; 1980.
19. Pilepich, M. V.; Asbell, S. O.; Krall, J. M.; Baewald, W. H.; Sause, W. T.; Rubin, P.; Emami, B. N.; Pidcock, G. M. Cor-relation of radiotherapeutic parameters and treatment related morbidity-an analysis of RTOG study 77-06. Int. J. Radiat. Oncol. Biol. Phys. 13:1007-1012; 1987.
20. Pilepich, M. V.; Krall, J. M.; Sause, W. T.; Johnson, R. J.; Russ, H. H.; Hanks, G. E.; Perez, C. A.; Zinninger, M.; Martz, K. L. Prognostic factors in carcinoma of the prostate-analysis of RTOG study 75-06. Int. J. Radiat. Oncol. Biol. Phys. 13:339-349; 1987.
21. Pontes, J. E.; Eisenkraft, S.; Watanabe, H.; Ohe, H.; Saitoh, M.; Murphy, G. P. Preoperative evaluation of localized prostatic carcinoma by transrectal ultrasonography. J. Urol. 134:289-291; 1985.
22. Roach, M.; Marquez, C.; Yuo, H. S.; Narayan, P.; Coleman, L.; Nseyo, U. O.; Navvab, Z.; Carroll, P. R. Predicting the risk of lymph node involvement using the pretreatment PSA and Gleason score in men with clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 28:33-37; 1994.
23. Rosen, E.; Cassady, J. R.; Connolly, J.; Chaffey, J. T. Radiotherapy for prostate carcinoma. The JCRT experience (1968-1978). II. Factors related to tumor control and complications. Int. J. Radiat. Oncol. Biol. Phys. 11:725-730; 1985.
24. Sandler, H. M.; McLaughlin, P. W.; Ten Haken, R. K.; Addison, H.; Forman, J.; Lichter, A. S. 3D conformal radiotherapy for the treatment of prostate cancer: Low risk of chronic rectal morbidity observed in a large series of patients. (Abstr.) Int. J. Radiat. Oncol. Biol. Phys. 27 (Suppl. 1):135; 1993.
25. Sandler, H. M.; Perez-Tamayo, C.; Randall, K.; Ten Haken, R. K.; Lichter, A. S. Dose escalation for stage C (T3) prostate cancer: Minimal rectal toxicity observed using conformal therapy. Radiother. Oncol. 23:53-54; 1992.
26. Scardino, P. T.; Shinohara, K.; Wheeler, T. M.; Carter, S. C. Staging of prostate cancer. Value of ultrasonography. Urol. Clin. North Am. 16(4):713-734; 1989.
27. Schultheiss, T. E.; Hanks, G. E.; Hunt, M. A.; Epstein, P.; Peter, R. Factors influencing incidence of acute grade II morbidity in conformal and standard radiation treatment of prostate cancer: Univariate and multivariate analysis. (Abstr.). Int. J. Radiat. Oncol. Biol. Phys. 27 (Suppl. 1):134; 1993.
28. Smit, W. G. J. M.; Helle, P. A.; vanPutten, W. Z. J.; Wijnmaalen, A. J.; Seldenrath, J. J.; vanderWerf-Messing, B. H. P. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int. J. Radiat. Oncol. Biol. Phys. 18:23-29; 1990.
29. Stamey, T. A.; Kabalin, J. N.; McNeal, J. E.; Johnstone, I. M.; Freiha, F.; Radwine, E. A.; Yang, N. Prostatic specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J. Urol. 141:1076-1083; 1989.
30. Ten Haken, R. K.; Perez-Tamayo, C.; Tesser, R. J.; McShan, D. L.; Fraass, B. A.; Lichter, A. S. Boost treatment of the prostate using shaped, fixed fields. Int. J. Radiat. Oncol. Biol. Phys. 16:193-200; 1989.
31. Villers, A. A.; McNeal, J. E.; Redwine, E. A.; Freiha, F. S.; Stamey, T. A. Pathogenesis and biological significance of seminal vesicle invasion in prostatic adenocarcinoma. J. Urol. 143:1183-1187; 1990.